FDA Backtracks on Withdrawing Amantadine Syrup Approval
Published Date: 9/4/2025
Notice
Summary
The FDA fixed a mistake about pulling approval for eight generic drug applications. One company, CMP Pharma, asked to keep their approval for amantadine syrup, and the FDA agreed, so that drug’s approval stays active. This update clears up confusion and keeps things fair for the companies involved, effective April 14, 2025.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Keeps Amantadine Syrup Approval
The FDA corrected a March 14, 2025 notice and kept approval of ANDA 075819 for amantadine hydrochloride syrup, 50 mg/5 mL, held by CMP Pharma, Inc. The original notice said the approval would be withdrawn as of April 14, 2025, but CMP Pharma timely asked to retain approval, so the approval remains in effect.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in